SCHEMBL1844867

SCHEMBL1844867

Cc1cc(OCCCC2CCN(c3nc(C4CCC4)no3)CC2)ccc1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.39
HRH3 Q9Y5N1 1/20 0.37
KCNH2 Q12809 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
PARP15 Q460N3 2/20 0.36
PARP10 Q53GL7 2/20 0.36
CHEK2 O96017 1/20 0.35
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAOA P21397 2/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434661 0.97 GPR119 (0.40) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL1841491 0.92 SMN1; SMN2 (0.37) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL1843407 0.91 GPR119 (0.37) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL1840885 0.89 GPR119 (0.38) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL1842605 0.87 GPR119 (0.38) GPR119HRH3NPC1RAB9APPARG
SCHEMBL1844406 0.86 HRH3 (0.37) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL2371149 0.86 GPR119 (0.40) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL2371015 0.86 GPR119 (0.40) GPR119HRH3KCNH2NPC1RAB9A
SCHEMBL2399814 0.85 GPR119 (0.51) GPR119KCNH2MAOA
SCHEMBL2371544 0.85 GPR119 (0.39) GPR119HRH3KCNH2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178054-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-07-21 US disclosed
US-20110178054-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-07-21 US disclosed
US-20110178054-A1 Heterocyclic GPCR Agonists PROSIDION LIMITED (GB) 2011-07-21 US disclosed
EP-2321305-A1 HETEROCYCLIC GPCR AGONISTS Prosidion Limited (GB) 2011-05-18 EP disclosed
WO-2010004348-A1 HETEROCYCLIC GPCR AGONISTS PROSIDION LIMITED (GB) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178054-A1 Heterocyclic GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885HRH3 406/4885KCNH2 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.